drugset / Trial / NCT00865982
Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer
Phase 2
Unknown
50 enrolled
Charite University, Berlin, Germany
Roche Pharma AG · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, patients with adenocarcinoma of the stomach, gastro-esophageal junction or the distal esophagus who seem operable with curative intent according to oncological and surgical assessment are treated with 3 preoperative cycles of DCX (Docetaxel, Cisplatin, Capecitabine) followed by surgical resection, followed by 3 postoperative cycles of DCX.
Timeline
- Start
- 2008-09
- Primary completion
- 2014-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1875 mg/m2 | Oral |
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |